nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—AGTR1—atherosclerosis	0.457	1	CbGaD
Eprosartan—ABCC2—Ezetimibe—atherosclerosis	0.0786	0.2	CbGbCtD
Eprosartan—ABCC2—Simvastatin—atherosclerosis	0.0731	0.186	CbGbCtD
Eprosartan—ABCC2—Lovastatin—atherosclerosis	0.0715	0.182	CbGbCtD
Eprosartan—ABCC2—Pravastatin—atherosclerosis	0.0715	0.182	CbGbCtD
Eprosartan—CYP2C9—Rosuvastatin—atherosclerosis	0.0264	0.0671	CbGbCtD
Eprosartan—CYP2C9—Simvastatin—atherosclerosis	0.0246	0.0624	CbGbCtD
Eprosartan—CYP2C9—Lovastatin—atherosclerosis	0.024	0.061	CbGbCtD
Eprosartan—CYP2C9—Pravastatin—atherosclerosis	0.024	0.061	CbGbCtD
Eprosartan—Losartan—AGTR1—atherosclerosis	0.00127	0.551	CrCbGaD
Eprosartan—AGTR1—artery—atherosclerosis	0.00117	0.232	CbGeAlD
Eprosartan—AGTR1—endothelium—atherosclerosis	0.000988	0.196	CbGeAlD
Eprosartan—AGTR1—blood vessel—atherosclerosis	0.000911	0.18	CbGeAlD
Eprosartan—Losartan—ACE—atherosclerosis	0.000734	0.318	CrCbGaD
Eprosartan—AGTR1—connective tissue—atherosclerosis	0.000467	0.0925	CbGeAlD
Eprosartan—AGTR1—cardiovascular system—atherosclerosis	0.000406	0.0805	CbGeAlD
Eprosartan—Sinusitis—Lovastatin—atherosclerosis	0.000388	0.0039	CcSEcCtD
Eprosartan—Depression—Simvastatin—atherosclerosis	0.000386	0.00388	CcSEcCtD
Eprosartan—Bronchitis—Niacin—atherosclerosis	0.000383	0.00386	CcSEcCtD
Eprosartan—Angina pectoris—Pravastatin—atherosclerosis	0.000382	0.00384	CcSEcCtD
Eprosartan—Sweating increased—Pravastatin—atherosclerosis	0.000382	0.00384	CcSEcCtD
Eprosartan—Sinusitis—Ezetimibe—atherosclerosis	0.000381	0.00383	CcSEcCtD
Eprosartan—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000379	0.00382	CcSEcCtD
Eprosartan—Flatulence—Rosuvastatin—atherosclerosis	0.000376	0.00378	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000365	0.00367	CcSEcCtD
Eprosartan—Sinusitis—Simvastatin—atherosclerosis	0.000363	0.00365	CcSEcCtD
Eprosartan—Pharyngitis—Ezetimibe—atherosclerosis	0.000362	0.00364	CcSEcCtD
Eprosartan—Oedema peripheral—Ezetimibe—atherosclerosis	0.000359	0.00361	CcSEcCtD
Eprosartan—AGTR1—adipose tissue—atherosclerosis	0.000358	0.071	CbGeAlD
Eprosartan—Depression—Pravastatin—atherosclerosis	0.000349	0.00351	CcSEcCtD
Eprosartan—Angioedema—Rosuvastatin—atherosclerosis	0.000349	0.00351	CcSEcCtD
Eprosartan—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000343	0.00345	CcSEcCtD
Eprosartan—Urinary tract infection—Pravastatin—atherosclerosis	0.00034	0.00342	CcSEcCtD
Eprosartan—Chills—Lovastatin—atherosclerosis	0.000333	0.00335	CcSEcCtD
Eprosartan—Cough—Rosuvastatin—atherosclerosis	0.000333	0.00335	CcSEcCtD
Eprosartan—Sinusitis—Pravastatin—atherosclerosis	0.000328	0.0033	CcSEcCtD
Eprosartan—Arthralgia—Rosuvastatin—atherosclerosis	0.000325	0.00327	CcSEcCtD
Eprosartan—Myalgia—Rosuvastatin—atherosclerosis	0.000325	0.00327	CcSEcCtD
Eprosartan—Rhinitis—Niacin—atherosclerosis	0.00032	0.00322	CcSEcCtD
Eprosartan—Flatulence—Lovastatin—atherosclerosis	0.000319	0.0032	CcSEcCtD
Eprosartan—Rhinitis—Pravastatin—atherosclerosis	0.000315	0.00317	CcSEcCtD
Eprosartan—Oedema peripheral—Niacin—atherosclerosis	0.000314	0.00316	CcSEcCtD
Eprosartan—Back pain—Lovastatin—atherosclerosis	0.000313	0.00315	CcSEcCtD
Eprosartan—Flatulence—Ezetimibe—atherosclerosis	0.000312	0.00314	CcSEcCtD
Eprosartan—Pharyngitis—Pravastatin—atherosclerosis	0.000312	0.00314	CcSEcCtD
Eprosartan—Chills—Simvastatin—atherosclerosis	0.000312	0.00314	CcSEcCtD
Eprosartan—Muscle spasms—Lovastatin—atherosclerosis	0.000311	0.00313	CcSEcCtD
Eprosartan—Visual impairment—Niacin—atherosclerosis	0.000307	0.00309	CcSEcCtD
Eprosartan—Back pain—Ezetimibe—atherosclerosis	0.000307	0.00309	CcSEcCtD
Eprosartan—Muscle spasms—Ezetimibe—atherosclerosis	0.000305	0.00307	CcSEcCtD
Eprosartan—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000305	0.00307	CcSEcCtD
Eprosartan—Tremor—Lovastatin—atherosclerosis	0.000303	0.00305	CcSEcCtD
Eprosartan—Visual impairment—Pravastatin—atherosclerosis	0.000303	0.00304	CcSEcCtD
Eprosartan—Losartan—ALB—atherosclerosis	0.000301	0.13	CrCbGaD
Eprosartan—Ill-defined disorder—Lovastatin—atherosclerosis	0.0003	0.00302	CcSEcCtD
Eprosartan—Flatulence—Simvastatin—atherosclerosis	0.000298	0.003	CcSEcCtD
Eprosartan—Tinnitus—Niacin—atherosclerosis	0.000297	0.00299	CcSEcCtD
Eprosartan—Angioedema—Lovastatin—atherosclerosis	0.000295	0.00297	CcSEcCtD
Eprosartan—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000294	0.00296	CcSEcCtD
Eprosartan—Tinnitus—Pravastatin—atherosclerosis	0.000293	0.00295	CcSEcCtD
Eprosartan—Malaise—Lovastatin—atherosclerosis	0.000292	0.00293	CcSEcCtD
Eprosartan—Muscle spasms—Simvastatin—atherosclerosis	0.000291	0.00292	CcSEcCtD
Eprosartan—Vertigo—Lovastatin—atherosclerosis	0.00029	0.00292	CcSEcCtD
Eprosartan—Angioedema—Ezetimibe—atherosclerosis	0.00029	0.00291	CcSEcCtD
Eprosartan—Chills—Niacin—atherosclerosis	0.000286	0.00288	CcSEcCtD
Eprosartan—Malaise—Ezetimibe—atherosclerosis	0.000286	0.00288	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000284	0.00285	CcSEcCtD
Eprosartan—Tremor—Simvastatin—atherosclerosis	0.000283	0.00285	CcSEcCtD
Eprosartan—Chills—Pravastatin—atherosclerosis	0.000282	0.00283	CcSEcCtD
Eprosartan—Insomnia—Rosuvastatin—atherosclerosis	0.000282	0.00283	CcSEcCtD
Eprosartan—Ill-defined disorder—Simvastatin—atherosclerosis	0.000281	0.00282	CcSEcCtD
Eprosartan—Palpitations—Ezetimibe—atherosclerosis	0.00028	0.00282	CcSEcCtD
Eprosartan—Paraesthesia—Rosuvastatin—atherosclerosis	0.00028	0.00281	CcSEcCtD
Eprosartan—Cough—Ezetimibe—atherosclerosis	0.000277	0.00278	CcSEcCtD
Eprosartan—Angioedema—Simvastatin—atherosclerosis	0.000276	0.00278	CcSEcCtD
Eprosartan—Chest pain—Lovastatin—atherosclerosis	0.000275	0.00277	CcSEcCtD
Eprosartan—Myalgia—Lovastatin—atherosclerosis	0.000275	0.00277	CcSEcCtD
Eprosartan—Arthralgia—Lovastatin—atherosclerosis	0.000275	0.00277	CcSEcCtD
Eprosartan—Anxiety—Lovastatin—atherosclerosis	0.000274	0.00276	CcSEcCtD
Eprosartan—Dyspepsia—Rosuvastatin—atherosclerosis	0.000274	0.00276	CcSEcCtD
Eprosartan—Flatulence—Niacin—atherosclerosis	0.000274	0.00275	CcSEcCtD
Eprosartan—Malaise—Simvastatin—atherosclerosis	0.000273	0.00274	CcSEcCtD
Eprosartan—Tension—Niacin—atherosclerosis	0.000272	0.00274	CcSEcCtD
Eprosartan—Discomfort—Lovastatin—atherosclerosis	0.000272	0.00274	CcSEcCtD
Eprosartan—Vertigo—Simvastatin—atherosclerosis	0.000272	0.00273	CcSEcCtD
Eprosartan—Chest pain—Ezetimibe—atherosclerosis	0.00027	0.00272	CcSEcCtD
Eprosartan—Arthralgia—Ezetimibe—atherosclerosis	0.00027	0.00272	CcSEcCtD
Eprosartan—Myalgia—Ezetimibe—atherosclerosis	0.00027	0.00272	CcSEcCtD
Eprosartan—Nervousness—Niacin—atherosclerosis	0.00027	0.00271	CcSEcCtD
Eprosartan—Flatulence—Pravastatin—atherosclerosis	0.000269	0.00271	CcSEcCtD
Eprosartan—Dry mouth—Lovastatin—atherosclerosis	0.000269	0.00271	CcSEcCtD
Eprosartan—Tension—Pravastatin—atherosclerosis	0.000268	0.0027	CcSEcCtD
Eprosartan—Muscle spasms—Niacin—atherosclerosis	0.000267	0.00269	CcSEcCtD
Eprosartan—Discomfort—Ezetimibe—atherosclerosis	0.000267	0.00268	CcSEcCtD
Eprosartan—Constipation—Rosuvastatin—atherosclerosis	0.000266	0.00268	CcSEcCtD
Eprosartan—Pain—Rosuvastatin—atherosclerosis	0.000266	0.00268	CcSEcCtD
Eprosartan—Nervousness—Pravastatin—atherosclerosis	0.000266	0.00267	CcSEcCtD
Eprosartan—Dry mouth—Ezetimibe—atherosclerosis	0.000264	0.00266	CcSEcCtD
Eprosartan—Muscle spasms—Pravastatin—atherosclerosis	0.000263	0.00264	CcSEcCtD
Eprosartan—Thrombocytopenia—Lovastatin—atherosclerosis	0.000258	0.0026	CcSEcCtD
Eprosartan—Arthralgia—Simvastatin—atherosclerosis	0.000257	0.00259	CcSEcCtD
Eprosartan—Myalgia—Simvastatin—atherosclerosis	0.000257	0.00259	CcSEcCtD
Eprosartan—Chest pain—Simvastatin—atherosclerosis	0.000257	0.00259	CcSEcCtD
Eprosartan—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000257	0.00258	CcSEcCtD
Eprosartan—Anxiety—Simvastatin—atherosclerosis	0.000257	0.00258	CcSEcCtD
Eprosartan—Tremor—Pravastatin—atherosclerosis	0.000256	0.00258	CcSEcCtD
Eprosartan—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000255	0.00256	CcSEcCtD
Eprosartan—Discomfort—Simvastatin—atherosclerosis	0.000254	0.00256	CcSEcCtD
Eprosartan—Angioedema—Niacin—atherosclerosis	0.000254	0.00255	CcSEcCtD
Eprosartan—Ill-defined disorder—Pravastatin—atherosclerosis	0.000254	0.00255	CcSEcCtD
Eprosartan—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000253	0.00255	CcSEcCtD
Eprosartan—Anorexia—Lovastatin—atherosclerosis	0.000252	0.00253	CcSEcCtD
Eprosartan—AGTR1—liver—atherosclerosis	0.000251	0.0498	CbGeAlD
Eprosartan—Angioedema—Pravastatin—atherosclerosis	0.00025	0.00251	CcSEcCtD
Eprosartan—Vertigo—Niacin—atherosclerosis	0.000249	0.00251	CcSEcCtD
Eprosartan—Syncope—Niacin—atherosclerosis	0.000249	0.0025	CcSEcCtD
Eprosartan—Urticaria—Rosuvastatin—atherosclerosis	0.000247	0.00249	CcSEcCtD
Eprosartan—Malaise—Pravastatin—atherosclerosis	0.000247	0.00248	CcSEcCtD
Eprosartan—Abdominal pain—Rosuvastatin—atherosclerosis	0.000246	0.00248	CcSEcCtD
Eprosartan—Vertigo—Pravastatin—atherosclerosis	0.000246	0.00247	CcSEcCtD
Eprosartan—Palpitations—Niacin—atherosclerosis	0.000245	0.00247	CcSEcCtD
Eprosartan—Loss of consciousness—Niacin—atherosclerosis	0.000244	0.00245	CcSEcCtD
Eprosartan—Cough—Niacin—atherosclerosis	0.000242	0.00244	CcSEcCtD
Eprosartan—Thrombocytopenia—Simvastatin—atherosclerosis	0.000242	0.00243	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00024	0.00242	CcSEcCtD
Eprosartan—Insomnia—Lovastatin—atherosclerosis	0.000239	0.0024	CcSEcCtD
Eprosartan—Cough—Pravastatin—atherosclerosis	0.000239	0.0024	CcSEcCtD
Eprosartan—Paraesthesia—Lovastatin—atherosclerosis	0.000237	0.00238	CcSEcCtD
Eprosartan—Arthralgia—Niacin—atherosclerosis	0.000236	0.00238	CcSEcCtD
Eprosartan—Myalgia—Niacin—atherosclerosis	0.000236	0.00238	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000236	0.00237	CcSEcCtD
Eprosartan—Anorexia—Simvastatin—atherosclerosis	0.000235	0.00237	CcSEcCtD
Eprosartan—Dyspnoea—Lovastatin—atherosclerosis	0.000235	0.00237	CcSEcCtD
Eprosartan—Insomnia—Ezetimibe—atherosclerosis	0.000234	0.00235	CcSEcCtD
Eprosartan—Myalgia—Pravastatin—atherosclerosis	0.000233	0.00234	CcSEcCtD
Eprosartan—Chest pain—Pravastatin—atherosclerosis	0.000233	0.00234	CcSEcCtD
Eprosartan—Arthralgia—Pravastatin—atherosclerosis	0.000233	0.00234	CcSEcCtD
Eprosartan—Paraesthesia—Ezetimibe—atherosclerosis	0.000232	0.00234	CcSEcCtD
Eprosartan—Dyspepsia—Lovastatin—atherosclerosis	0.000232	0.00234	CcSEcCtD
Eprosartan—Anxiety—Pravastatin—atherosclerosis	0.000232	0.00233	CcSEcCtD
Eprosartan—Dry mouth—Niacin—atherosclerosis	0.000231	0.00233	CcSEcCtD
Eprosartan—Dyspnoea—Ezetimibe—atherosclerosis	0.000231	0.00232	CcSEcCtD
Eprosartan—Discomfort—Pravastatin—atherosclerosis	0.00023	0.00231	CcSEcCtD
Eprosartan—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000229	0.00231	CcSEcCtD
Eprosartan—Decreased appetite—Lovastatin—atherosclerosis	0.000229	0.00231	CcSEcCtD
Eprosartan—Dyspepsia—Ezetimibe—atherosclerosis	0.000228	0.00229	CcSEcCtD
Eprosartan—Fatigue—Lovastatin—atherosclerosis	0.000228	0.00229	CcSEcCtD
Eprosartan—Constipation—Lovastatin—atherosclerosis	0.000226	0.00227	CcSEcCtD
Eprosartan—Pain—Lovastatin—atherosclerosis	0.000226	0.00227	CcSEcCtD
Eprosartan—Decreased appetite—Ezetimibe—atherosclerosis	0.000225	0.00226	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000225	0.00226	CcSEcCtD
Eprosartan—Asthenia—Rosuvastatin—atherosclerosis	0.000223	0.00225	CcSEcCtD
Eprosartan—Insomnia—Simvastatin—atherosclerosis	0.000223	0.00225	CcSEcCtD
Eprosartan—Fatigue—Ezetimibe—atherosclerosis	0.000223	0.00224	CcSEcCtD
Eprosartan—Shock—Niacin—atherosclerosis	0.000223	0.00224	CcSEcCtD
Eprosartan—Paraesthesia—Simvastatin—atherosclerosis	0.000222	0.00223	CcSEcCtD
Eprosartan—Constipation—Ezetimibe—atherosclerosis	0.000221	0.00223	CcSEcCtD
Eprosartan—Pain—Ezetimibe—atherosclerosis	0.000221	0.00223	CcSEcCtD
Eprosartan—Tachycardia—Niacin—atherosclerosis	0.000221	0.00222	CcSEcCtD
Eprosartan—Pruritus—Rosuvastatin—atherosclerosis	0.00022	0.00222	CcSEcCtD
Eprosartan—Dyspnoea—Simvastatin—atherosclerosis	0.00022	0.00221	CcSEcCtD
Eprosartan—Hyperhidrosis—Niacin—atherosclerosis	0.000219	0.0022	CcSEcCtD
Eprosartan—Thrombocytopenia—Pravastatin—atherosclerosis	0.000218	0.0022	CcSEcCtD
Eprosartan—Feeling abnormal—Lovastatin—atherosclerosis	0.000217	0.00219	CcSEcCtD
Eprosartan—Dyspepsia—Simvastatin—atherosclerosis	0.000217	0.00219	CcSEcCtD
Eprosartan—Anorexia—Niacin—atherosclerosis	0.000216	0.00217	CcSEcCtD
Eprosartan—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000216	0.00217	CcSEcCtD
Eprosartan—Hyperhidrosis—Pravastatin—atherosclerosis	0.000216	0.00217	CcSEcCtD
Eprosartan—Decreased appetite—Simvastatin—atherosclerosis	0.000215	0.00216	CcSEcCtD
Eprosartan—Feeling abnormal—Ezetimibe—atherosclerosis	0.000213	0.00215	CcSEcCtD
Eprosartan—Diarrhoea—Rosuvastatin—atherosclerosis	0.000213	0.00214	CcSEcCtD
Eprosartan—Fatigue—Simvastatin—atherosclerosis	0.000213	0.00214	CcSEcCtD
Eprosartan—Anorexia—Pravastatin—atherosclerosis	0.000213	0.00214	CcSEcCtD
Eprosartan—Hypotension—Niacin—atherosclerosis	0.000212	0.00213	CcSEcCtD
Eprosartan—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000212	0.00213	CcSEcCtD
Eprosartan—Constipation—Simvastatin—atherosclerosis	0.000211	0.00212	CcSEcCtD
Eprosartan—Pain—Simvastatin—atherosclerosis	0.000211	0.00212	CcSEcCtD
Eprosartan—Urticaria—Lovastatin—atherosclerosis	0.00021	0.00211	CcSEcCtD
Eprosartan—Abdominal pain—Lovastatin—atherosclerosis	0.000209	0.0021	CcSEcCtD
Eprosartan—Body temperature increased—Lovastatin—atherosclerosis	0.000209	0.0021	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000206	0.00208	CcSEcCtD
Eprosartan—Dizziness—Rosuvastatin—atherosclerosis	0.000206	0.00207	CcSEcCtD
Eprosartan—Urticaria—Ezetimibe—atherosclerosis	0.000206	0.00207	CcSEcCtD
Eprosartan—Insomnia—Niacin—atherosclerosis	0.000205	0.00206	CcSEcCtD
Eprosartan—Abdominal pain—Ezetimibe—atherosclerosis	0.000205	0.00206	CcSEcCtD
Eprosartan—Body temperature increased—Ezetimibe—atherosclerosis	0.000205	0.00206	CcSEcCtD
Eprosartan—Paraesthesia—Niacin—atherosclerosis	0.000204	0.00205	CcSEcCtD
Eprosartan—Feeling abnormal—Simvastatin—atherosclerosis	0.000203	0.00205	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000203	0.00204	CcSEcCtD
Eprosartan—Dyspnoea—Niacin—atherosclerosis	0.000202	0.00203	CcSEcCtD
Eprosartan—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000202	0.00203	CcSEcCtD
Eprosartan—Insomnia—Pravastatin—atherosclerosis	0.000202	0.00203	CcSEcCtD
Eprosartan—Somnolence—Niacin—atherosclerosis	0.000201	0.00203	CcSEcCtD
Eprosartan—Paraesthesia—Pravastatin—atherosclerosis	0.0002	0.00202	CcSEcCtD
Eprosartan—Dyspepsia—Niacin—atherosclerosis	0.000199	0.00201	CcSEcCtD
Eprosartan—Dyspnoea—Pravastatin—atherosclerosis	0.000199	0.002	CcSEcCtD
Eprosartan—Decreased appetite—Niacin—atherosclerosis	0.000197	0.00198	CcSEcCtD
Eprosartan—Dyspepsia—Pravastatin—atherosclerosis	0.000196	0.00198	CcSEcCtD
Eprosartan—Rash—Rosuvastatin—atherosclerosis	0.000196	0.00197	CcSEcCtD
Eprosartan—Dermatitis—Rosuvastatin—atherosclerosis	0.000196	0.00197	CcSEcCtD
Eprosartan—Urticaria—Simvastatin—atherosclerosis	0.000196	0.00197	CcSEcCtD
Eprosartan—CYP2C9—cardiovascular system—atherosclerosis	0.000196	0.0388	CbGeAlD
Eprosartan—Body temperature increased—Simvastatin—atherosclerosis	0.000195	0.00196	CcSEcCtD
Eprosartan—Abdominal pain—Simvastatin—atherosclerosis	0.000195	0.00196	CcSEcCtD
Eprosartan—Headache—Rosuvastatin—atherosclerosis	0.000195	0.00196	CcSEcCtD
Eprosartan—Hypersensitivity—Lovastatin—atherosclerosis	0.000194	0.00196	CcSEcCtD
Eprosartan—Decreased appetite—Pravastatin—atherosclerosis	0.000194	0.00195	CcSEcCtD
Eprosartan—Pain—Niacin—atherosclerosis	0.000194	0.00195	CcSEcCtD
Eprosartan—Fatigue—Pravastatin—atherosclerosis	0.000192	0.00194	CcSEcCtD
Eprosartan—Constipation—Pravastatin—atherosclerosis	0.000191	0.00192	CcSEcCtD
Eprosartan—Pain—Pravastatin—atherosclerosis	0.000191	0.00192	CcSEcCtD
Eprosartan—Hypersensitivity—Ezetimibe—atherosclerosis	0.000191	0.00192	CcSEcCtD
Eprosartan—Asthenia—Lovastatin—atherosclerosis	0.000189	0.0019	CcSEcCtD
Eprosartan—Pruritus—Lovastatin—atherosclerosis	0.000187	0.00188	CcSEcCtD
Eprosartan—Asthenia—Ezetimibe—atherosclerosis	0.000186	0.00187	CcSEcCtD
Eprosartan—Gastrointestinal pain—Niacin—atherosclerosis	0.000185	0.00186	CcSEcCtD
Eprosartan—Nausea—Rosuvastatin—atherosclerosis	0.000185	0.00186	CcSEcCtD
Eprosartan—Feeling abnormal—Pravastatin—atherosclerosis	0.000184	0.00185	CcSEcCtD
Eprosartan—Pruritus—Ezetimibe—atherosclerosis	0.000183	0.00184	CcSEcCtD
Eprosartan—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000182	0.00184	CcSEcCtD
Eprosartan—Hypersensitivity—Simvastatin—atherosclerosis	0.000182	0.00183	CcSEcCtD
Eprosartan—ABCC2—liver—atherosclerosis	0.000182	0.036	CbGeAlD
Eprosartan—Diarrhoea—Lovastatin—atherosclerosis	0.000181	0.00182	CcSEcCtD
Eprosartan—Urticaria—Niacin—atherosclerosis	0.00018	0.00181	CcSEcCtD
Eprosartan—Body temperature increased—Niacin—atherosclerosis	0.000179	0.0018	CcSEcCtD
Eprosartan—Abdominal pain—Niacin—atherosclerosis	0.000179	0.0018	CcSEcCtD
Eprosartan—Urticaria—Pravastatin—atherosclerosis	0.000177	0.00178	CcSEcCtD
Eprosartan—Asthenia—Simvastatin—atherosclerosis	0.000177	0.00178	CcSEcCtD
Eprosartan—Diarrhoea—Ezetimibe—atherosclerosis	0.000177	0.00178	CcSEcCtD
Eprosartan—Abdominal pain—Pravastatin—atherosclerosis	0.000176	0.00177	CcSEcCtD
Eprosartan—Body temperature increased—Pravastatin—atherosclerosis	0.000176	0.00177	CcSEcCtD
Eprosartan—Pruritus—Simvastatin—atherosclerosis	0.000175	0.00176	CcSEcCtD
Eprosartan—Dizziness—Lovastatin—atherosclerosis	0.000174	0.00176	CcSEcCtD
Eprosartan—Dizziness—Ezetimibe—atherosclerosis	0.000171	0.00172	CcSEcCtD
Eprosartan—Diarrhoea—Simvastatin—atherosclerosis	0.000169	0.0017	CcSEcCtD
Eprosartan—Vomiting—Lovastatin—atherosclerosis	0.000168	0.00169	CcSEcCtD
Eprosartan—Hypersensitivity—Niacin—atherosclerosis	0.000167	0.00168	CcSEcCtD
Eprosartan—Rash—Lovastatin—atherosclerosis	0.000166	0.00167	CcSEcCtD
Eprosartan—Dermatitis—Lovastatin—atherosclerosis	0.000166	0.00167	CcSEcCtD
Eprosartan—Headache—Lovastatin—atherosclerosis	0.000165	0.00166	CcSEcCtD
Eprosartan—Vomiting—Ezetimibe—atherosclerosis	0.000165	0.00166	CcSEcCtD
Eprosartan—Hypersensitivity—Pravastatin—atherosclerosis	0.000164	0.00165	CcSEcCtD
Eprosartan—Dizziness—Simvastatin—atherosclerosis	0.000163	0.00164	CcSEcCtD
Eprosartan—Rash—Ezetimibe—atherosclerosis	0.000163	0.00164	CcSEcCtD
Eprosartan—Dermatitis—Ezetimibe—atherosclerosis	0.000163	0.00164	CcSEcCtD
Eprosartan—Asthenia—Niacin—atherosclerosis	0.000163	0.00164	CcSEcCtD
Eprosartan—Headache—Ezetimibe—atherosclerosis	0.000162	0.00163	CcSEcCtD
Eprosartan—Pruritus—Niacin—atherosclerosis	0.00016	0.00161	CcSEcCtD
Eprosartan—Asthenia—Pravastatin—atherosclerosis	0.00016	0.00161	CcSEcCtD
Eprosartan—Pruritus—Pravastatin—atherosclerosis	0.000158	0.00159	CcSEcCtD
Eprosartan—Vomiting—Simvastatin—atherosclerosis	0.000157	0.00158	CcSEcCtD
Eprosartan—Nausea—Lovastatin—atherosclerosis	0.000157	0.00158	CcSEcCtD
Eprosartan—Rash—Simvastatin—atherosclerosis	0.000156	0.00157	CcSEcCtD
Eprosartan—Dermatitis—Simvastatin—atherosclerosis	0.000155	0.00156	CcSEcCtD
Eprosartan—Diarrhoea—Niacin—atherosclerosis	0.000155	0.00156	CcSEcCtD
Eprosartan—Headache—Simvastatin—atherosclerosis	0.000155	0.00156	CcSEcCtD
Eprosartan—Nausea—Ezetimibe—atherosclerosis	0.000154	0.00155	CcSEcCtD
Eprosartan—Diarrhoea—Pravastatin—atherosclerosis	0.000153	0.00154	CcSEcCtD
Eprosartan—Dizziness—Niacin—atherosclerosis	0.00015	0.00151	CcSEcCtD
Eprosartan—Dizziness—Pravastatin—atherosclerosis	0.000148	0.00148	CcSEcCtD
Eprosartan—Nausea—Simvastatin—atherosclerosis	0.000147	0.00147	CcSEcCtD
Eprosartan—Vomiting—Niacin—atherosclerosis	0.000144	0.00145	CcSEcCtD
Eprosartan—Rash—Niacin—atherosclerosis	0.000143	0.00144	CcSEcCtD
Eprosartan—Dermatitis—Niacin—atherosclerosis	0.000143	0.00144	CcSEcCtD
Eprosartan—Headache—Niacin—atherosclerosis	0.000142	0.00143	CcSEcCtD
Eprosartan—Vomiting—Pravastatin—atherosclerosis	0.000142	0.00143	CcSEcCtD
Eprosartan—Rash—Pravastatin—atherosclerosis	0.000141	0.00142	CcSEcCtD
Eprosartan—Dermatitis—Pravastatin—atherosclerosis	0.000141	0.00141	CcSEcCtD
Eprosartan—Headache—Pravastatin—atherosclerosis	0.00014	0.00141	CcSEcCtD
Eprosartan—Nausea—Niacin—atherosclerosis	0.000135	0.00135	CcSEcCtD
Eprosartan—Nausea—Pravastatin—atherosclerosis	0.000133	0.00133	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CASR—atherosclerosis	0.000126	0.00296	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CX3CL1—atherosclerosis	0.000124	0.0029	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.000123	0.00288	CbGpPWpGaD
Eprosartan—CYP2C9—liver—atherosclerosis	0.000121	0.024	CbGeAlD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.00012	0.00281	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.00012	0.00281	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.00012	0.00281	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CNR2—atherosclerosis	0.000117	0.00275	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.000117	0.00274	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.000117	0.00274	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—HRH1—atherosclerosis	0.000116	0.00271	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—atherosclerosis	0.000114	0.00268	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCG4—atherosclerosis	0.000111	0.0026	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—AGT—atherosclerosis	0.000108	0.00254	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—AGT—atherosclerosis	0.000107	0.00251	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCG8—atherosclerosis	0.000106	0.00249	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—HMOX1—atherosclerosis	0.000105	0.00247	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—atherosclerosis	0.000105	0.00246	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRH1—atherosclerosis	0.000105	0.00246	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TGFB1—atherosclerosis	0.000105	0.00246	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.000103	0.0024	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL3—atherosclerosis	0.000101	0.00237	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—F2—atherosclerosis	0.0001	0.00235	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	9.92e-05	0.00232	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—F2—atherosclerosis	9.89e-05	0.00232	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GSTM1—atherosclerosis	9.82e-05	0.0023	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—atherosclerosis	9.79e-05	0.00229	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GPX1—atherosclerosis	9.74e-05	0.00228	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	9.69e-05	0.00227	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—AGER—atherosclerosis	9.47e-05	0.00222	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP7A1—atherosclerosis	9.16e-05	0.00215	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—EDNRA—atherosclerosis	9.14e-05	0.00214	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCR2—atherosclerosis	9.14e-05	0.00214	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP7A1—atherosclerosis	9.04e-05	0.00212	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	8.96e-05	0.0021	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—GHRL—atherosclerosis	8.9e-05	0.00209	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCL2—atherosclerosis	8.81e-05	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	8.65e-05	0.00203	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	8.58e-05	0.00201	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP27A1—atherosclerosis	8.47e-05	0.00199	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—PDGFB—atherosclerosis	8.45e-05	0.00198	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCG1—atherosclerosis	8.4e-05	0.00197	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP27A1—atherosclerosis	8.35e-05	0.00196	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—KNG1—atherosclerosis	7.81e-05	0.00183	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CYP7A1—atherosclerosis	7.62e-05	0.00179	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCL4—atherosclerosis	7.59e-05	0.00178	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—UTS2—atherosclerosis	7.45e-05	0.00175	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	7.18e-05	0.00168	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CASR—atherosclerosis	7.14e-05	0.00167	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—atherosclerosis	6.97e-05	0.00163	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TRPV1—atherosclerosis	6.85e-05	0.00161	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—UTS2—atherosclerosis	6.76e-05	0.00159	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CNR2—atherosclerosis	6.64e-05	0.00156	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	6.63e-05	0.00155	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCG5—atherosclerosis	6.59e-05	0.00155	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—EDN1—atherosclerosis	6.59e-05	0.00154	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL5—atherosclerosis	6.53e-05	0.00153	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CX3CR1—atherosclerosis	6.48e-05	0.00152	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CASR—atherosclerosis	6.48e-05	0.00152	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CX3CL1—atherosclerosis	6.36e-05	0.00149	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRH1—atherosclerosis	6.2e-05	0.00145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CNR2—atherosclerosis	6.03e-05	0.00141	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LDLRAP1—atherosclerosis	6.02e-05	0.00141	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	5.91e-05	0.00139	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—atherosclerosis	5.73e-05	0.00134	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLTP—atherosclerosis	5.66e-05	0.00133	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—AGT—atherosclerosis	5.47e-05	0.00128	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCL3—atherosclerosis	5.18e-05	0.00121	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—EDNRA—atherosclerosis	5.16e-05	0.00121	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CCR2—atherosclerosis	5.16e-05	0.00121	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—F2—atherosclerosis	5.05e-05	0.00118	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GHRL—atherosclerosis	5.03e-05	0.00118	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCG8—atherosclerosis	4.91e-05	0.00115	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LTA4H—atherosclerosis	4.91e-05	0.00115	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CETP—atherosclerosis	4.88e-05	0.00114	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOA4—atherosclerosis	4.87e-05	0.00114	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	4.85e-05	0.00114	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EDNRA—atherosclerosis	4.69e-05	0.0011	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCR2—atherosclerosis	4.69e-05	0.0011	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	4.67e-05	0.0011	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GHRL—atherosclerosis	4.57e-05	0.00107	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL2—atherosclerosis	4.5e-05	0.00106	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL4—atherosclerosis	4.48e-05	0.00105	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—KNG1—atherosclerosis	4.42e-05	0.00103	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PLAT—atherosclerosis	4.3e-05	0.00101	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOA2—atherosclerosis	4.19e-05	0.000982	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KNG1—atherosclerosis	4.01e-05	0.00094	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—atherosclerosis	4e-05	0.000938	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—UTS2—atherosclerosis	4e-05	0.000936	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCG1—atherosclerosis	3.88e-05	0.00091	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CX3CR1—atherosclerosis	3.83e-05	0.000898	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASR—atherosclerosis	3.83e-05	0.000898	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—atherosclerosis	3.78e-05	0.000887	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CX3CL1—atherosclerosis	3.76e-05	0.00088	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—atherosclerosis	3.73e-05	0.000875	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—EDN1—atherosclerosis	3.72e-05	0.000872	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CCL5—atherosclerosis	3.69e-05	0.000865	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PLG—atherosclerosis	3.66e-05	0.000857	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	3.65e-05	0.000855	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	3.65e-05	0.000855	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	3.58e-05	0.00084	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CNR2—atherosclerosis	3.56e-05	0.000835	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—atherosclerosis	3.56e-05	0.000834	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MMP3—atherosclerosis	3.55e-05	0.000833	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	3.55e-05	0.000831	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	3.52e-05	0.000825	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PRKCG—atherosclerosis	3.51e-05	0.000823	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EDN1—atherosclerosis	3.38e-05	0.000792	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—HMOX1—atherosclerosis	3.38e-05	0.000791	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCL5—atherosclerosis	3.35e-05	0.000786	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	3.25e-05	0.000762	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—APOB—atherosclerosis	3.23e-05	0.000758	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PRKCG—atherosclerosis	3.19e-05	0.000747	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VWF—atherosclerosis	3.17e-05	0.000744	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOC3—atherosclerosis	3.15e-05	0.000739	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LDLR—atherosclerosis	3.14e-05	0.000735	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AGT—atherosclerosis	3.09e-05	0.000724	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	3.08e-05	0.000723	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	3.08e-05	0.000723	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	3.08e-05	0.000723	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	3.08e-05	0.000723	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL3—atherosclerosis	3.06e-05	0.000718	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	3.05e-05	0.000714	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	2.94e-05	0.000689	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NCF1—atherosclerosis	2.93e-05	0.000687	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—F2—atherosclerosis	2.85e-05	0.000669	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	2.82e-05	0.000661	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AGT—atherosclerosis	2.81e-05	0.000657	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCR2—atherosclerosis	2.77e-05	0.000649	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EDNRA—atherosclerosis	2.77e-05	0.000649	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CYBA—atherosclerosis	2.76e-05	0.000646	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—atherosclerosis	2.73e-05	0.00064	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PPARA—atherosclerosis	2.73e-05	0.000639	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	2.71e-05	0.000636	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PLAT—atherosclerosis	2.7e-05	0.000633	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PARP1—atherosclerosis	2.7e-05	0.000633	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GHRL—atherosclerosis	2.7e-05	0.000633	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LDLRAP1—atherosclerosis	2.68e-05	0.000629	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	2.62e-05	0.000615	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—F2—atherosclerosis	2.59e-05	0.000607	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—APOA1—atherosclerosis	2.56e-05	0.0006	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLTP—atherosclerosis	2.52e-05	0.000591	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—atherosclerosis	2.48e-05	0.000581	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KNG1—atherosclerosis	2.37e-05	0.000555	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	2.34e-05	0.000548	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	2.32e-05	0.000544	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCL2—atherosclerosis	2.31e-05	0.000541	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	2.31e-05	0.000541	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PLG—atherosclerosis	2.29e-05	0.000538	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	2.25e-05	0.000528	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG8—atherosclerosis	2.19e-05	0.000513	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LTA4H—atherosclerosis	2.19e-05	0.000513	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SOCS3—atherosclerosis	2.17e-05	0.000509	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	2.16e-05	0.000506	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP3—atherosclerosis	2.1e-05	0.000492	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF2—atherosclerosis	2.09e-05	0.00049	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	2.04e-05	0.000478	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOB—atherosclerosis	2.03e-05	0.000475	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—atherosclerosis	2.03e-05	0.000475	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—atherosclerosis	2.01e-05	0.000471	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EDN1—atherosclerosis	2e-05	0.000468	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL5—atherosclerosis	1.98e-05	0.000464	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LPL—atherosclerosis	1.94e-05	0.000454	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PRKCG—atherosclerosis	1.88e-05	0.000441	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SPP1—atherosclerosis	1.83e-05	0.00043	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—atherosclerosis	1.83e-05	0.000428	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	1.82e-05	0.000426	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG1—atherosclerosis	1.73e-05	0.000405	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFB—atherosclerosis	1.7e-05	0.000398	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AGT—atherosclerosis	1.66e-05	0.000388	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LCAT—atherosclerosis	1.63e-05	0.000381	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FABP4—atherosclerosis	1.63e-05	0.000381	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—atherosclerosis	1.62e-05	0.000381	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOE—atherosclerosis	1.62e-05	0.000381	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CAV1—atherosclerosis	1.61e-05	0.000377	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOA1—atherosclerosis	1.61e-05	0.000376	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA4—atherosclerosis	1.6e-05	0.000374	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP7A1—atherosclerosis	1.57e-05	0.000367	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—atherosclerosis	1.55e-05	0.000363	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—F2—atherosclerosis	1.53e-05	0.000359	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.49e-05	0.00035	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—atherosclerosis	1.47e-05	0.000343	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP27A1—atherosclerosis	1.45e-05	0.00034	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.43e-05	0.000334	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAPK3—atherosclerosis	1.4e-05	0.000329	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.39e-05	0.000326	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—INS—atherosclerosis	1.39e-05	0.000325	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	1.37e-05	0.000322	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA2—atherosclerosis	1.37e-05	0.000322	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALOX15—atherosclerosis	1.37e-05	0.000322	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	1.37e-05	0.000322	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL2—atherosclerosis	1.36e-05	0.00032	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG5—atherosclerosis	1.36e-05	0.000318	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.36e-05	0.000318	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1—atherosclerosis	1.34e-05	0.000314	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LPA—atherosclerosis	1.31e-05	0.000307	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SERPINE1—atherosclerosis	1.27e-05	0.000299	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BGN—atherosclerosis	1.27e-05	0.000297	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.26e-05	0.000295	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA5—atherosclerosis	1.26e-05	0.000294	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.22e-05	0.000286	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOS3—atherosclerosis	1.22e-05	0.000285	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	1.21e-05	0.000283	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.2e-05	0.00028	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.18e-05	0.000278	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.18e-05	0.000277	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALOX5—atherosclerosis	1.17e-05	0.000274	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—atherosclerosis	1.08e-05	0.000253	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.08e-05	0.000253	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.05e-05	0.000245	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—atherosclerosis	1.04e-05	0.000244	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.04e-05	0.000244	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LIPC—atherosclerosis	1.04e-05	0.000244	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOC3—atherosclerosis	1.03e-05	0.000242	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LDLR—atherosclerosis	1.03e-05	0.000241	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—atherosclerosis	1.03e-05	0.00024	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CETP—atherosclerosis	1e-05	0.000235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—atherosclerosis	9.76e-06	0.000229	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFKB1—atherosclerosis	9.66e-06	0.000226	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SCARB1—atherosclerosis	9.62e-06	0.000225	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK8—atherosclerosis	9.49e-06	0.000222	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—atherosclerosis	9.47e-06	0.000222	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.36e-06	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMGCR—atherosclerosis	9.08e-06	0.000213	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—atherosclerosis	8.76e-06	0.000205	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—atherosclerosis	8.68e-06	0.000203	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK3—atherosclerosis	8.29e-06	0.000194	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.19e-06	0.000192	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCA1—atherosclerosis	8.09e-06	0.00019	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—atherosclerosis	8.04e-06	0.000189	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMOX1—atherosclerosis	6.94e-06	0.000163	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOB—atherosclerosis	6.65e-06	0.000156	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—atherosclerosis	6.47e-06	0.000152	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LPL—atherosclerosis	6.35e-06	0.000149	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX1—atherosclerosis	6.2e-06	0.000145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—atherosclerosis	6.06e-06	0.000142	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CD36—atherosclerosis	6.03e-06	0.000141	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—atherosclerosis	5.72e-06	0.000134	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARA—atherosclerosis	5.61e-06	0.000131	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—atherosclerosis	5.59e-06	0.000131	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AGT—atherosclerosis	5.43e-06	0.000127	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOE—atherosclerosis	5.32e-06	0.000125	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAV1—atherosclerosis	5.27e-06	0.000124	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOA1—atherosclerosis	5.26e-06	0.000123	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—atherosclerosis	4.8e-06	0.000113	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—atherosclerosis	4.64e-06	0.000109	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—INS—atherosclerosis	4.55e-06	0.000107	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—atherosclerosis	4.17e-06	9.77e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NOS3—atherosclerosis	3.99e-06	9.35e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.65e-06	8.55e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—atherosclerosis	1.83e-06	4.3e-05	CbGpPWpGaD
